Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15

Autores
Bissio, E.; Barbás, M. G.; Bouzas, M. B.; Cudola, A.; Salomon, Horacio Eduardo; Espínola, L.; Fernández Giuliano, S.; Kademián, S.; Mammana, L.; Suarez Ornani, M. L.; Ravasi, G.; Vila, M.; Zapiola, I.; Falistocco, C.
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. Objectives: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHOproposed methodology. Methods: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. Results: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean±SD age was 35±11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2%PI-RAMs) and 13% (+4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. Conclusions: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina´s Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.
Fil: Bissio, E.. Fundación Centro de Estudios Infectológicos; Argentina
Fil: Barbás, M. G.. Laboratorio Central de Córdoba; Argentina
Fil: Bouzas, M. B.. Hospital Muñiz; Argentina
Fil: Cudola, A.. Laboratorio Central de Córdoba; Argentina
Fil: Salomon, Horacio Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Espínola, L.. Provincia de Buenos Aires. Ministerio de Salud; Argentina
Fil: Fernández Giuliano, S.. Hospital Muñiz; Argentina
Fil: Kademián, S.. Laboratorio Central de Córdoba; Argentina
Fil: Mammana, L.. Hospital Muñiz; Argentina
Fil: Suarez Ornani, M. L.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Ravasi, G.. Organización Panamericana de la Salud; Estados Unidos
Fil: Vila, M.. Organización Panamericana de la Salud; Argentina
Fil: Zapiola, I.. Hospital Muñiz; Argentina
Fil: Falistocco, C.. Provincia de Buenos Aires. Ministerio de Salud; Argentina
Materia
Hiv
Aids
Treatment
Argentina
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/47971
Acceder
id CONICETDig_7e2d2da8775999bfefd3c7f8839041f2
oai_identifier_str oai:ri.conicet.gov.ar:11336/47971
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15Bissio, E.Barbás, M. G.Bouzas, M. B.Cudola, A.Salomon, Horacio EduardoEspínola, L.Fernández Giuliano, S.Kademián, S.Mammana, L.Suarez Ornani, M. L.Ravasi, G.Vila, M.Zapiola, I.Falistocco, C.HivAidsTreatmentArgentinahttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Background: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. Objectives: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHOproposed methodology. Methods: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. Results: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean±SD age was 35±11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2%PI-RAMs) and 13% (+4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. Conclusions: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina´s Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.Fil: Bissio, E.. Fundación Centro de Estudios Infectológicos; ArgentinaFil: Barbás, M. G.. Laboratorio Central de Córdoba; ArgentinaFil: Bouzas, M. B.. Hospital Muñiz; ArgentinaFil: Cudola, A.. Laboratorio Central de Córdoba; ArgentinaFil: Salomon, Horacio Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Espínola, L.. Provincia de Buenos Aires. Ministerio de Salud; ArgentinaFil: Fernández Giuliano, S.. Hospital Muñiz; ArgentinaFil: Kademián, S.. Laboratorio Central de Córdoba; ArgentinaFil: Mammana, L.. Hospital Muñiz; ArgentinaFil: Suarez Ornani, M. L.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Ravasi, G.. Organización Panamericana de la Salud; Estados UnidosFil: Vila, M.. Organización Panamericana de la Salud; ArgentinaFil: Zapiola, I.. Hospital Muñiz; ArgentinaFil: Falistocco, C.. Provincia de Buenos Aires. Ministerio de Salud; ArgentinaOxford University Press2017-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/47971Bissio, E.; Barbás, M. G.; Bouzas, M. B.; Cudola, A.; Salomon, Horacio Eduardo; et al.; Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15; Oxford University Press; Journal of Antimicrobial Chemotherapy; 72; 2; 2-2017; 504-5100305-7453CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkw445info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/jac/article/72/2/504/2374139info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:52:39Zoai:ri.conicet.gov.ar:11336/47971instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:52:39.825CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
title Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
spellingShingle Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
Bissio, E.
Hiv
Aids
Treatment
Argentina
title_short Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
title_full Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
title_fullStr Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
title_full_unstemmed Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
title_sort Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15
dc.creator.none.fl_str_mv Bissio, E.
Barbás, M. G.
Bouzas, M. B.
Cudola, A.
Salomon, Horacio Eduardo
Espínola, L.
Fernández Giuliano, S.
Kademián, S.
Mammana, L.
Suarez Ornani, M. L.
Ravasi, G.
Vila, M.
Zapiola, I.
Falistocco, C.
author Bissio, E.
author_facet Bissio, E.
Barbás, M. G.
Bouzas, M. B.
Cudola, A.
Salomon, Horacio Eduardo
Espínola, L.
Fernández Giuliano, S.
Kademián, S.
Mammana, L.
Suarez Ornani, M. L.
Ravasi, G.
Vila, M.
Zapiola, I.
Falistocco, C.
author_role author
author2 Barbás, M. G.
Bouzas, M. B.
Cudola, A.
Salomon, Horacio Eduardo
Espínola, L.
Fernández Giuliano, S.
Kademián, S.
Mammana, L.
Suarez Ornani, M. L.
Ravasi, G.
Vila, M.
Zapiola, I.
Falistocco, C.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hiv
Aids
Treatment
Argentina
topic Hiv
Aids
Treatment
Argentina
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Background: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. Objectives: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHOproposed methodology. Methods: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. Results: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean±SD age was 35±11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2%PI-RAMs) and 13% (+4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. Conclusions: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina´s Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.
Fil: Bissio, E.. Fundación Centro de Estudios Infectológicos; Argentina
Fil: Barbás, M. G.. Laboratorio Central de Córdoba; Argentina
Fil: Bouzas, M. B.. Hospital Muñiz; Argentina
Fil: Cudola, A.. Laboratorio Central de Córdoba; Argentina
Fil: Salomon, Horacio Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Espínola, L.. Provincia de Buenos Aires. Ministerio de Salud; Argentina
Fil: Fernández Giuliano, S.. Hospital Muñiz; Argentina
Fil: Kademián, S.. Laboratorio Central de Córdoba; Argentina
Fil: Mammana, L.. Hospital Muñiz; Argentina
Fil: Suarez Ornani, M. L.. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Ravasi, G.. Organización Panamericana de la Salud; Estados Unidos
Fil: Vila, M.. Organización Panamericana de la Salud; Argentina
Fil: Zapiola, I.. Hospital Muñiz; Argentina
Fil: Falistocco, C.. Provincia de Buenos Aires. Ministerio de Salud; Argentina
description Background: In Argentina, current national guidelines recommend starting with NNRTI-based regimens. Recently, there have been some local reports regarding concerning levels of NNRTI-transmitted resistance, but surveillance has never been carried out at a national level. Objectives: To determine the prevalence of HIV drug resistance in people starting ART in Argentina using a WHOproposed methodology. Methods: This was a cross-sectional, nationally representative study. Twenty-five antiretroviral-dispensing sites throughout the country were randomly chosen to enrol at least 330 persons starting ART, to generate a point prevalence estimate of resistance-associated mutations (RAMs) with a 5% CI (for the total population and for those without antiretroviral exposure). All consecutive patients older than 18 years starting or restarting ART in the chosen clinics were eligible. Samples were processed with Trugene and analysed using the Stanford algorithm. Results: Between August 2014 and March 2015, we obtained 330 samples from people starting ART. The mean±SD age was 35±11 years, 63.4% were male, 16.6% had prior antiretroviral exposure and the median (IQR) CD4 count was 275 cells/mm3 (106-461). The prevalence of RAMs found was 14% (±4%) for the whole population (3% NRTI-RAMs; 11% NNRTI-RAMs and 2%PI-RAMs) and 13% (+4%) for those without prior antiretroviral exposure (3%, 10% and 2%, respectively). The most common mutation was K103N. Conclusions: This surveillance study showed concerning levels of HIV drug resistance in Argentina, especially to NNRTIs. Due to this finding, Argentina´s Ministry of Health guidelines will change, recommending performing a resistance test for everyone before starting ART. If this is taken up properly, it also might function as a continuing surveillance tool.
publishDate 2017
dc.date.none.fl_str_mv 2017-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/47971
Bissio, E.; Barbás, M. G.; Bouzas, M. B.; Cudola, A.; Salomon, Horacio Eduardo; et al.; Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15; Oxford University Press; Journal of Antimicrobial Chemotherapy; 72; 2; 2-2017; 504-510
0305-7453
CONICET Digital
CONICET
url http://hdl.handle.net/11336/47971
identifier_str_mv Bissio, E.; Barbás, M. G.; Bouzas, M. B.; Cudola, A.; Salomon, Horacio Eduardo; et al.; Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014–15; Oxford University Press; Journal of Antimicrobial Chemotherapy; 72; 2; 2-2017; 504-510
0305-7453
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkw445
info:eu-repo/semantics/altIdentifier/url/https://academic.oup.com/jac/article/72/2/504/2374139
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269173992914944
score 13.13397

Publicaciones similares